In a filing, Ultragenyx Pharmaceutical Inc revealed its Chief Financial Officer Horn Howard unloaded Company’s shares for reported $72114.0 on Mar 06 ’25. In the deal valued at $40.40 per share,1,785 shares were sold. As a result of this transaction, Horn Howard now holds 106,169 shares worth roughly $3.71 million.
Then, Kassberg Thomas Richard sold 6,028 shares, generating $253,779 in total proceeds. Upon selling the shares at $42.10, the CBO & EVP now owns 265,238 shares.
Before that, Parschauer Karah Herdman sold 12,846 shares. Ultragenyx Pharmaceutical Inc shares valued at $540,817 were divested by the EVP and Chief Legal Officer at a price of $42.10 per share. As a result of the transaction, Parschauer Karah Herdman now holds 75,287 shares, worth roughly $2.63 million.
Goldman upgraded its Ultragenyx Pharmaceutical Inc [RARE] rating to a Buy from a a Neutral in a research note published on June 06, 2024; the price target was increased to $67 from $56. A number of analysts have revised their coverage, including RBC Capital Mkts’s analysts, who began to cover the stock in late April with a ‘”an Outperform”‘ rating. Wells Fargo began covering RARE with “an Overweight” recommendation on December 08, 2023.
Price Performance Review of RARE
On Monday, Ultragenyx Pharmaceutical Inc [NASDAQ:RARE] saw its stock jump 2.28% to $34.92. Over the last five days, the stock has gained 8.65%. Ultragenyx Pharmaceutical Inc shares have fallen nearly -17.00% since the year began. Nevertheless, the stocks have fallen -31.12% over the past one year. While a 52-week high of $60.37 was reached on 02/06/25, a 52-week low of $29.59 was recorded on 04/09/25. SMA at 50 days reached $39.68, while 200 days put it at $46.75.
Levels Of Support And Resistance For RARE Stock
The 24-hour chart illustrates a support level at 34.12, which if violated will result in even more drops to 33.32. On the upside, there is a resistance level at 35.41. A further resistance level may holdings at 35.90. The Relative Strength Index (RSI) on the 14-day chart is 44.32, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.71, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 44.57%. Stochastics %K at 45.83% indicates the stock is a holding.
How much short interest is there in Ultragenyx Pharmaceutical Inc?
A steep rise in short interest was recorded in Ultragenyx Pharmaceutical Inc stocks on 2025-03-31, dropping by 62198.0 shares to a total of 4.53 million shares. Yahoo Finance data shows the prior-month short interest on 2025-02-28 was 4.59 million shares. There was a decline of -1.37%, which implies that there is a negative sentiment for the stock.
